LOGO

Vaxine has private company status

• Vaxine is currently registered as a private Australian company and its shares are currently not traded on any stock exchange
• Whilst Vaxine has no current plans for an IPO, Vaxine is happy to discuss such possibilities with potential investors including venture capital companies and stock broking firms
• Vaxine is currently actively seeking additional licensing and/or development partners to help commercialize its vaccine technologies

Vaxine actively protects its intellectual property through development of patents, trademarks and commercial secrets

• To maximise the value of the company, Vaxine actively protects its intellectual property through development of patents, trademarks and commercial secrets
• Advax(TM) is the trademark for a family of plant sugar-based vaccine adjuvants developed by Vaxine
• In addition to its Advax(TM) patent coverage, Vaxine also holds international patents over vaccine technology to prevent type 1 (autoimmune) diabetes.
• To protect the Advax(TM) family of adjuvants, Vaxine has been granted multiple US and international patents. As new data is generated and advances made, Vaxine continues to apply for new patents over these technology improvements.